{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:41:34Z","timestamp":1762429294727,"version":"build-2065373602"},"reference-count":107,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.drudis.2017.04.014","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T00:18:02Z","timestamp":1493425082000},"page":"1017-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia"],"prefix":"10.1016","volume":"22","author":[{"given":"John C.","family":"Talpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2017.04.014_bib0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0010","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.4088\/JCP.1006e12","article-title":"Cognitive impairment and functional outcome in schizophrenia and bipolar disorder","volume":"67","author":"Green","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1176\/appi.ajp.2008.07111713","article-title":"Relationship of cognition and psychopathology to functional impairment in schizophrenia","volume":"165","author":"Mohamed","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0020","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/schbul\/sbr189","article-title":"Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data","volume":"39","author":"Sakurai","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.drudis.2017.04.014_bib0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0920-9964(97)00112-6","article-title":"The evolving concept of schizophrenia: from Kraepelin to the present and future","volume":"28","author":"Andreasen","year":"1997","journal-title":"Schizophr. Res."},{"issue":"Suppl. 9","key":"10.1016\/j.drudis.2017.04.014_bib0040","first-page":"3","article-title":"Cognitive impairment and functional outcome in schizophrenia and bipolar disorder","volume":"67","author":"Green","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2010.11.008","article-title":"The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study","volume":"126","author":"Kern","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2010.09.015","article-title":"Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial","volume":"125","author":"Keefe","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0060","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1176\/appi.ajp.2011.11010039","article-title":"The NIMH-CATIE Schizophrenia Study: what did we learn?","volume":"168","author":"Lieberman","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0065","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2004.09.010","article-title":"Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia","volume":"72","author":"Marder","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1176\/appi.ajp.161.1.25","article-title":"Schizophrenia, IX: cognition in schizophrenia-the MATRICS initiative","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0085","unstructured":"NEWMEDS Consortium. Available at: http:\/\/www.newmeds-europe.com."},{"key":"10.1016\/j.drudis.2017.04.014_bib0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/schbul\/sbi047","volume":"31","author":"Nuechterlein","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.drudis.2017.04.014_bib0095","first-page":"5","article-title":"Psychiatric drug development: diagnosing a crisis","volume":"2013","author":"Hyman","year":"2013","journal-title":"Cerebrum"},{"key":"10.1016\/j.drudis.2017.04.014_bib0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0028-3908(95)00028-5","article-title":"Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands","volume":"34","author":"Briggs","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40263-015-0260-0","article-title":"The therapeutic potential of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia","volume":"29","author":"Beinat","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2017.04.014_bib0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/01.pra.0000442938.61575.c2","article-title":"The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.drudis.2017.04.014_bib0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2008.03.023","article-title":"Visual perception and its impairment in schizophrenia","volume":"64","author":"Butler","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/schbul\/sbn156","article-title":"Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS","volume":"35","author":"Green","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.drudis.2017.04.014_bib0125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10548-013-0306-x","article-title":"Source activation of P300 correlates with negative symptom severity in patients with schizophrenia","volume":"27","author":"Kim","year":"2014","journal-title":"Brain Topogr."},{"key":"10.1016\/j.drudis.2017.04.014_bib0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0006-3223(98)00290-X","article-title":"P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia","volume":"46","author":"Ford","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0135","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/1469-8986.3660667","article-title":"Schizophrenia: the broken P300 and beyond","volume":"36","author":"Ford","year":"1999","journal-title":"Psychophysiology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0140","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.neubiorev.2013.06.016","article-title":"Animal models and measures of perceptual processing in schizophrenia","volume":"37","author":"Siegel","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.drudis.2017.04.014_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuropharm.2012.06.040","article-title":"Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study","volume":"64","author":"Winterer","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bcp.2015.05.011","article-title":"Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia","volume":"97","author":"Kohlhaas","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.pra.0000442935.15833.c5","article-title":"Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.drudis.2017.04.014_bib0160","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/npp.2015.176","article-title":"Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia","volume":"40","author":"Keefe","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0165","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2015.15010093","article-title":"A randomized trial to assess the efficacy and safety of ABT-126, a selective alpha7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia","author":"Haig","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0170","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/acps.12412","article-title":"How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview","volume":"132","author":"Stubbs","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.drudis.2017.04.014_bib0175","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2013.12.011","article-title":"Use of SERMs for treatment in postmenopausal women","volume":"142","author":"Pinkerton","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0180","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/j.1755-5949.2010.00163.x","article-title":"Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Sanchez","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.drudis.2017.04.014_bib0185","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1192\/bjp.150.5.662","article-title":"Epidemiology of puerperal psychoses","volume":"150","author":"Kendell","year":"1987","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02900216","article-title":"What do we really know about late-onset schizophrenia?","volume":"247","author":"Riecher-Rossler","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0195","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.psyneuen.2004.03.008","article-title":"Effect of long-term estrogen therapy on dopaminergic responsivity in post-menopausal women\u2013a preliminary study","volume":"29","author":"Craig","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2012.08.016","article-title":"Estrogen augmentation in schizophrenia: a quantitative review of current evidence","volume":"141","author":"Begemann","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.euroneuro.2013.11.012","article-title":"Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial","volume":"24","author":"Huerta-Ramos","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0210","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/mp.2015.11","article-title":"Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia","volume":"20","author":"Weickert","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0215","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","author":"Muldoon","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.drudis.2017.04.014_bib0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2125.1995.tb04458.x","article-title":"Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia","volume":"39","author":"Cutler","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JAD-2010-100180","article-title":"Statins and cognitive functioning in the elderly: a population-based study","volume":"21","author":"Benito-Leon","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2017.04.014_bib0230","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1474-4422(13)70227-8","article-title":"Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial","volume":"12","author":"van der Vaart","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.expneurol.2010.04.006","article-title":"Statins: multiple neuroprotective mechanisms in neurodegenerative diseases","volume":"230","author":"Wang","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbacli.2015.06.007","article-title":"Simvastatin augmentation for recent-onset psychotic disorder: a study protocol","volume":"4","author":"Begemann","year":"2015","journal-title":"BBA Clin."},{"key":"10.1016\/j.drudis.2017.04.014_bib0245","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/2045125313511487","article-title":"Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study","volume":"4","author":"Chaudhry","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2015.07.018","article-title":"Clinical studies of neuroinflammatory mechanisms in schizophrenia","volume":"176","author":"Watkins","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0255","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"Muller","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0260","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2017.04.014_bib0265","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0270","doi-asserted-by":"crossref","first-page":"e004158","DOI":"10.1136\/bmjopen-2013-004158","article-title":"Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist-protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol","volume":"4","author":"Ishoy","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2017.04.014_bib0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.peptides.2014.08.014","article-title":"Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice","volume":"61","author":"Lennox","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.drudis.2017.04.014_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2012.03.014","article-title":"Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice","volume":"35","author":"Porter","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.drudis.2017.04.014_bib0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0295","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00001756-199504190-00011","article-title":"Ketamine activates psychosis and alters limbic blood flow in schizophrenia","volume":"6","author":"Lahti","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.drudis.2017.04.014_bib0300","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00213-016-4291-0","article-title":"Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: testing an experimental medicine strategy","volume":"233","author":"Bhakta","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drudis.2017.04.014_bib0305","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2008.200","article-title":"A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.euroneuro.2007.07.008","article-title":"Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study","volume":"18","author":"Krivoy","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0315","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1017\/S0033291716000398","article-title":"Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study","volume":"46","author":"Veerman","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.drudis.2017.04.014_bib0320","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0140-6736(90)91237-5","article-title":"Effect of famotidine on deficit symptoms of schizophrenia","volume":"335","author":"Kaminsky","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2017.04.014_bib0325","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0b013e3182970490","article-title":"A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia","volume":"33","author":"Meskanen","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0330","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.4088\/JCP.13f08707","article-title":"Famotidine augmentation in schizophrenia: hope or hype?","volume":"74","author":"Andrade","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0335","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fendo.2015.00090","article-title":"A role for oxytocin in the etiology and treatment of schizophrenia","volume":"6","author":"Rich","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0340","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopsych.2015.07.025","article-title":"A review of oxytocin\u2019s effects on the positive, negative, and cognitive domains of schizophrenia","volume":"79","author":"Feifel","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0345","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neubiorev.2015.04.012","article-title":"The association between autism and schizophrenia spectrum disorders: a review of eight alternate models of co-occurrence","volume":"55","author":"Chisholm","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.drudis.2017.04.014_bib0350","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/gm546","article-title":"Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice","volume":"6","author":"Doherty","year":"2014","journal-title":"Genome Med."},{"key":"10.1016\/j.drudis.2017.04.014_bib0355","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/mp.2014.29","article-title":"De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability","volume":"19","author":"McCarthy","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0360","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0006-8993(83)90478-X","article-title":"Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF","volume":"262","author":"Mens","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0365","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0370","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.psyneuen.2012.11.019","article-title":"Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research","volume":"38","author":"Guastella","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0375","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.88","article-title":"Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets","volume":"15","author":"Bespalov","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2017.04.014_bib0380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1523\/JNEUROSCI.21-01-00035.2001","article-title":"Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition","volume":"21","author":"Wayment","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0385","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cne.1092","article-title":"Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization","volume":"432","author":"Lewis","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0390","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0306-4522(02)00556-0","article-title":"Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function","volume":"116","author":"Matsumoto","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2017.04.014_bib0395","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2174\/156652411798062386","article-title":"Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia","volume":"11","author":"Gupta","year":"2011","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.drudis.2017.04.014_bib0400","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs.10.206","article-title":"Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia","volume":"12","author":"Bitsios","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2017.04.014_bib0405","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00023210-200721070-00002","article-title":"Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors","volume":"21","author":"Apud","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2017.04.014_bib0410","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12017-016-8392-z","article-title":"The role of a catechol-O-methyltransferase (COMT) Val158Met genetic polymorphism in schizophrenia: a systematic review and updated meta-analysis on 32,816 subjects","volume":"18","author":"Gonzalez-Castro","year":"2016","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.drudis.2017.04.014_bib0415","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.npp.1301227","article-title":"Tolcapone improves cognition and cortical information processing in normal human subjects","volume":"32","author":"Apud","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0420","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1523\/JNEUROSCI.1124-04.2004","article-title":"Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex","volume":"24","author":"Tunbridge","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson\u2019s disease: liver toxicity and clinical efficacy","volume":"4","author":"Borges","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.drudis.2017.04.014_bib0430","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40263-013-0082-x","article-title":"Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteers","volume":"27","author":"Magalona","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2017.04.014_bib0435","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/jm100210p","article-title":"Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia","volume":"53","author":"Pinard","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.04.014_bib0440","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","article-title":"Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia","volume":"62","author":"Alberati","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0445","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-013-3260-0","article-title":"The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey","volume":"231","author":"Eddins","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drudis.2017.04.014_bib0450","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuroimage.2011.11.090","article-title":"Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography","volume":"75","author":"Borroni","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.drudis.2017.04.014_bib0455","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/npp.2012.212","article-title":"Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers","volume":"38","author":"Martin-Facklam","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2017.04.014_bib0460","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1208\/s12248-014-9639-y","article-title":"Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin","volume":"16","author":"Parrott","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.drudis.2017.04.014_bib0465","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","article-title":"Glycine transport inhibitors in the treatment of schizophrenia","volume":"213","author":"Javitt","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0470","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ntt.2007.07.001","article-title":"Baseline behavior, but not sensitivity to stimulant drugs, differs among spontaneously hypertensive, Wistar-Kyoto, and Sprague-Dawley rat strains","volume":"29","author":"Ferguson","year":"2007","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0475","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00441-013-1694-7","article-title":"Touching on translation","volume":"354","author":"Talpos","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.drudis.2017.04.014_bib0480","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0892-0362(96)00027-X","article-title":"CANTAB battery: proposed utility in neurotoxicology","volume":"18","author":"Fray","year":"1996","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0485","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ntt.2009.08.011","article-title":"The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys","volume":"32","author":"Rodriguez","year":"2010","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0490","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neubiorev.2010.01.012","article-title":"Assessing cognitive function in clinical trials of schizophrenia","volume":"34","author":"Barnett","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.drudis.2017.04.014_bib0495","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1037\/a0022794","article-title":"Effect of methylphenidate on motivation in children with attention-deficit\/hyperactivity disorder","volume":"19","author":"Chelonis","year":"2011","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2017.04.014_bib0500","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cobeha.2015.04.011","article-title":"Using intermediate cognitive endpoints to facilitate translational research in psychosis","volume":"4","author":"Gilmour","year":"2015","journal-title":"Curr. Opin. Behav. Sci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0505","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/7854_2016_1","article-title":"Relating translational neuroimaging and amperometric endpoints: utility for neuropsychiatric drug discovery","volume":"28","author":"Li","year":"2016","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.drudis.2017.04.014_bib0510","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.neubiorev.2013.09.011","article-title":"Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models","volume":"37","author":"Moore","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.drudis.2017.04.014_bib0515","doi-asserted-by":"crossref","first-page":"e0147215","DOI":"10.1371\/journal.pone.0147215","article-title":"When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis","volume":"11","author":"Scannell","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.04.014_bib0520","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1176\/appi.ajp.2009.09020264","article-title":"A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia","volume":"167","author":"Dickinson","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0525","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes","volume":"168","author":"Wykes","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2017.04.014_bib0530","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/schbul\/sbp115","article-title":"The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements","volume":"36","author":"Dixon","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.drudis.2017.04.014_bib0535","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4155\/ppa.12.82","article-title":"Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004\u20132012)","volume":"2","author":"Lindsley","year":"2013","journal-title":"Pharm. Pat. Anal."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617302209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617302209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:31:39Z","timestamp":1761222699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644617302209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":107,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1359644617302209"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2017.04.014","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2017.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}